PLXDC1 anticorps (C-Term)
Aperçu rapide pour PLXDC1 anticorps (C-Term) (ABIN1881662)
Antigène
Voir toutes PLXDC1 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- AA 466-494, C-Term
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogène
- This PLXDC1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 466-494 amino acids from the C-terminal region of human PLXDC1.
-
Isotype
- Ig Fraction
-
-
-
-
Indications d'application
- WB: 1:1000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- 4 °C,-20 °C
-
Date de péremption
- 6 months
-
-
-
: "Preferential expression of the secreted and membrane forms of tumor endothelial marker 7 transcripts in osteosarcoma." dans: Anticancer research, Vol. 29, Issue 11, pp. 4317-22, (2009) (PubMed).
: "TEM7 (PLXDC1) in neovascular endothelial cells of fibrovascular membranes from patients with proliferative diabetic retinopathy." dans: Investigative ophthalmology & visual science, Vol. 49, Issue 7, pp. 3151-7, (2008) (PubMed).
: "High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma." dans: Gene, Vol. 399, Issue 2, pp. 137-43, (2007) (PubMed).
: "Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R." dans: Cancer research, Vol. 64, Issue 23, pp. 8507-11, (2004) (PubMed).
-
-
-